Vir Biotechnology Files 8-K on Security Holder Vote

Ticker: VIR · Form: 8-K · Filed: 2024-05-29T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: VIR

TL;DR

VIR filed an 8-K for a shareholder vote - details TBD.

AI Summary

Vir Biotechnology, Inc. filed an 8-K on May 29, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the nature of the vote or any outcomes.

Why It Matters

This filing indicates a formal process involving shareholder decisions, which could impact corporate governance or strategic direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Vir Biotechnology's security holders?

The filing does not specify the exact matters submitted for a vote.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 29, 2024.

What is the principal executive office address for Vir Biotechnology?

The address is 1800 Owens Street, Suite 900, San Francisco, California 94158.

What is the IRS Employer Identification Number for Vir Biotechnology?

The IRS Employer Identification Number is 81-2730369.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

From the Filing

0001193125-24-149139.txt : 20240529 0001193125-24-149139.hdr.sgml : 20240529 20240529160602 ACCESSION NUMBER: 0001193125-24-149139 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240529 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240529 DATE AS OF CHANGE: 20240529 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 24998344 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 d771470d8k.htm 8-K 8-K false 0001706431 0001706431 2024-05-29 2024-05-29     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024     Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter)       Delaware   001-39083   81-2730369 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of principal executive offices, including zip code) (415) 906-4324 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value   VIR   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.07 Submission of Matters to a Vote of Security Holders. On May 29, 2024, Vir Biotechnology, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 1, 2024, the record date for the Annual Meeting, 135,843,977 shares of Company common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Proposal 1. Election of Directors The Company’s stockholders elected the four persons listed below as Class II Directors, each to serve

View on Read The Filing